Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Earlier, in our immunoproteomic analysis, we found that peptidyl-prolyl cis-trans isomerase A (PpiA) protein-containing fractions induced significantly higher interferon-gamma (IFN-γ) response in LTBI than in PTB.
|
26546406 |
2015 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these, 37 (32%) presented LTBI - tuberculin skin test was positive in 18 (49%) patients; interferon gamma release test was positive in 14 (38%) patients and undetermined in seven (19%); and there was a history of exposure in 12 (32%) patients.
|
31206406 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidence and risk factors of latent tuberculosis tests conversion (interferon gamma release assays [IGRA], tuberculin skin tests [TST], and chest radiography [CXR]) with clinical outcomes were studied.
|
29757355 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of tuberculin skin test and interferon gamma release assay for diagnosis of latent tuberculosis infection in pediatric candidates of renal transplantation.
|
29388291 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicated that subjects with remote LTBI showed significantly higher whole-blood interferon-gamma responses to M. tuberculosis latency antigen Rv2628 than did individuals with recent infection, active tuberculosis and controls (p<0.003), whereas no significant differences between these groups were found for other latency antigens tested (Rv2626c, Rv2627c, Rv2031c and Rv2032).
|
19926735 |
2010 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The laboratory diagnosis of latent tuberculosis infection (LTBI) is mainly performed with interferon gamma release assays (IGRAs).
|
31533984 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
At our institution, CXR was performed for all patients undergoing a tuberculin skin test (TST) and/or an interferon-gamma release assay (IGRA) at the LTBI screening visit.
|
30261981 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel electrochemiluminescence (ECL) immunosensor based on the potential-resolved strategy was first developed for simultaneous determination of triple latent tuberculosis infection (LTBI) markers with high sensitivity, interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2.
|
28828860 |
2017 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon gamma release assay (IGRA) was used for the diagnosis of LTBI.
|
31561559 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proposed ECL-sensing platform is simple, sensitive, accurate, reliable, and specific to the detection of rare IFN-γ and IL-2 in human serum and provides a valuable protocol for facilitating fast and precise diagnosis of LTBI.
|
28497690 |
2017 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tuberculin skin test (TST) and interferon gamma release assays (IGRAs) are two methods for detection of LTBI.
|
29427966 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interferon-gamma (IFN-γ) releasing assay (IGRA) is widely used for latent tuberculosis infection (LTBI) diagnosis.
|
31432637 |
2020 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Mycobacterium tuberculosis</i>-Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4<sup>+</sup> T Cell-Dependent IFN-γ Production despite the Presence of Polyfunctional T Cells within the Airways.
|
31541022 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tuberculin skin and Interferon-gamma release assay tests used currently for the diagnosis of TB infection cannot distinguish between active disease and latent tuberculosis infection (LTBI) and hence new and sensitive protein markers need to be identified for the diagnosis.
|
29154992 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two doses of either M72/AS01<sub>E</sub> or placebo intramuscularly 1 month apart.
|
30280651 |
2018 |
Latent Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a cross-sectional analysis of baseline data from a UK cohort study which enrolled participants at risk of latent tuberculosis infection (LTBI, defined as a positive result for either of the two interferon gamma release assays).
|
29764958 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon Gamma Release Assay in response to PE35/PPE68 proteins: a promising diagnostic method for diagnosis of latent tuberculosis.
|
28840843 |
2017 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-three of twenty-six proteins induced an IFN-γ response in PBMCs of persons with active or latent tuberculosis.
|
23169589 |
2012 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since T-lymphocyte production of interferon-gamma (IFN-γ) in response to Mycobacterium tuberculosis (Mtb) antigens fails to differentiate disease from latent infection, we applied a comprehensive profiling methodology to define immune biomarkers that reliably predict a patient's TB risk.
|
27006526 |
2016 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Latent tuberculosis infection (LTBI) is diagnosed immunologically using the Mantoux tuberculin skin test (TST) or interferon-gamma release assays (IGRAs).
|
30514511 |
2018 |
Latent Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Estimating the annual risk of tuberculosis infection in Japan from interferon-gamma release assay data.
|
30315813 |
2019 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined IFN-γ and TNF-α release assay for differentiating active tuberculosis from latent tuberculosis infection.
|
29746954 |
2018 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peripheral blood mononuclear cells stimulated with peptide pools covering the full length of Rv2654 induced interferon- gamma release in 10 of 19 patients with TB.
|
14976597 |
2004 |
Latent Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection.
|
21967766 |
2011 |
Latent Tuberculosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We compared unstimulated interferon-gamma levels between LTBI and non-LTBI groups using the Wilcoxon rank sum test.
|
30212453 |
2018 |